BRIEF published on 05/29/2026 at 16:05, 3 months 19 days ago Vanguard Discloses Position in Schroders under Takeover Code Disclosure Takeover Code Schroders Plc Vanguard Group Stock Positions
BRIEF published on 05/29/2026 at 16:04, 3 months 19 days ago The Vanguard Group, Inc. Discloses Position in Beazley plc Disclosure The Vanguard Group Takeover Code Shareholding Beazley Plc
PRESS RELEASE published on 05/29/2026 at 16:00, 3 months 19 days ago Form 8.3 - The Vanguard Group, Inc.: Schroders plc The Vanguard Group, Inc. discloses 2.56% stake in Schroders plc as per Form 8.3 filing on 29-May-2026 Form 8.3 Schroders Plc Financial Filing Vanguard Group Stake Disclosure
PRESS RELEASE published on 05/29/2026 at 15:59, 3 months 19 days ago Form 8.3 - The Vanguard Group, Inc.: Beazley plc The Vanguard Group, Inc. discloses a 5.03% ownership of Beazley plc's relevant securities in a Form 8.3 filing Form 8.3 Disclosure Vanguard Group Ownership Beazley Plc
BRIEF published on 05/28/2026 at 15:28, 3 months 20 days ago Vanguard Group Discloses Position in Tate & Lyle plc The Vanguard Group Takeover Code Securities Disclosure Share Dealings Tate & Lyle
BRIEF published on 05/28/2026 at 15:27, 3 months 20 days ago Vanguard Discloses Stake in Spire Healthcare Form 8.3 Spire Healthcare Vanguard Securities Interest Equity Disclosure
BRIEF published on 05/28/2026 at 15:25, 3 months 20 days ago The Vanguard Group Discloses Position in Schroders plc Form 8.3 Takeover Code Securities Disclosure Schroders Plc Vanguard Group
BRIEF published on 05/28/2026 at 15:25, 3 months 20 days ago The Vanguard Group Reports Stake in NCC Group plc The Vanguard Group Takeover Code Stake Disclosure Share Position NCC Group Plc
BRIEF published on 05/28/2026 at 15:24, 3 months 20 days ago The Vanguard Group Discloses Position in JTC plc Securities Form 8.3 Takeover Code Vanguard Group JTC Plc
PRESS RELEASE published on 05/28/2026 at 15:23, 3 months 20 days ago Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc The Vanguard Group, Inc. discloses owning 4.74% of Tate & Lyle plc's relevant securities as of 27 May 2026, with recent trading activity Trading The Vanguard Group, Inc. Relevant Securities Disclosure Tate & Lyle Plc
Published on 09/18/2026 at 00:25, 23 minutes ago CoTec Holdings Corp. Announces Initial Closing of Private Placement of Unsecured Convertible Debentures
Published on 09/17/2026 at 22:15, 2 hours 33 minutes ago Rocky Shore Gold Announces Non-Brokered Private Placement
Published on 09/17/2026 at 22:15, 2 hours 33 minutes ago Vanta Attends 2026 All-In Summit in Los Angeles, a Leading Gathering of Business, Investment and Industry Leaders
Published on 09/17/2026 at 22:05, 2 hours 43 minutes ago Loop Industries Forms Strategic Alternatives Committee to Maximize Shareholder Value
Published on 09/17/2026 at 15:55, 8 hours 53 minutes ago Empress Announces Agreement to Acquire Tongon Gold Stream and Secures Debt Financing
Published on 09/17/2026 at 19:00, 5 hours 48 minutes ago Max Verstappen Passes All 100 Karts in 14 Laps in Red Bull's Max vs 100
Published on 09/17/2026 at 18:58, 5 hours 50 minutes ago EQS-Adhoc: H2APEX Group SCA: General Partner of H2APEX Group SCA resolves to prepare for the transfer of its stock exchange listing from the Regulated Market (Prime Standard) to the Scale segment of the Frankfur
Published on 09/17/2026 at 18:25, 6 hours 23 minutes ago Magentic raises $18M to build the AI workforce for the physical world
Published on 09/17/2026 at 18:10, 6 hours 38 minutes ago A robust adjusted EBIT margin of 18.8%, driven by solid organic revenue growth of 7.4%
Published on 09/17/2026 at 17:46, 7 hours 2 minutes ago RBI categorically denies the allegations of short-seller report
Published on 09/17/2026 at 17:40, 7 hours 8 minutes ago Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Published on 09/16/2026 at 17:45, 1 day 7 hours ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 17 hours ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
